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Iron Metabolism and its Disorders
Introduction
Systemic inflammation is accompanied by profound
changes in iron distribution, mainly under the influence of
hepcidin, leading to sequestration of iron in macrophages of
the reticuloendothelial system, and ultimately anemia of
inflammation.1 This redistribution of iron may represent an
effective defense mechanism against a variety of pathogens
that need iron for replication and growth. The fact that this
iron withholding strategy is such a highly conserved part of
the innate immune response illustrates that iron homeostasis
and immunity are closely related. In agreement with this, sev-
eral studies in animal models have revealed immune modula-
tory effects of both iron and iron chelation: Iron sucrose has
been shown to potentiate the inflammatory response and
associated mortality,2 while iron chelation appears to attenu-
ate inflammation and improve outcome in murine models of
inflammation and sepsis.3-6 The immune modulatory effects
of iron supplements and chelators are mainly attributed to
their ability to potentiate or reduce the formation of reactive
oxygen species (ROS). A subfraction of non-transferrin bound
catalytically active iron, labile plasma iron (LPI), is thought to
be responsible, as this free iron is able to easily donate or
accept electrons, thereby fueling redox reactions. Oxidative
stress is associated with propagation of the immune
response,7 endothelial dysfunction,8,9 and contributes to the
organ damage that occurs during systemic inflammation.10 In
agreement with this, anti-oxidants exert anti-inflammatory
effects.11,12 As such, iron chelation has been suggested to be a
valuable adjuvant therapy during infection for two distinct
reasons: 1) inhibition of bacterial growth; and 2) protection of
organs against inflammation-induced oxidative stress. 
Effects of iron status on the immune response have up till
now mainly been investigated in in vitro and in animal models,
often using supra-therapeutic dosages of iron donors or iron
chelators. Data on the effect of iron loading and iron chelation
during systemic inflammation in humans are lacking. The
objectives of the present study were to investigate the acute
effect of therapeutic dosages of iron loading and iron chela-
tion therapy on iron homeostasis, oxidative stress, the innate
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In this double-blind randomized placebo-controlled trial involving 30 healthy male volunteers we investigated the
acute effects of iron loading (single dose of 1.25 mg/kg iron sucrose) and iron chelation therapy (single dose of 30
mg/kg deferasirox) on iron parameters, oxidative stress, the innate immune response, and subclinical organ injury
during experimental human endotoxemia. The administration of iron sucrose induced a profound increase in plas-
ma malondialdehyde 1 h after administration (433±37% of baseline;  P<0.0001), but did not potentiate the endo-
toxemia-induced increase in malondialdehyde, as was seen 3 h after endotoxin administration in the placebo
group (P=0.34) and the iron chelation group (P=0.008). Endotoxemia resulted in an initial increase in serum iron
levels and transferrin saturation that was accompanied by an increase in labile plasma iron, especially when trans-
ferrin saturation reached levels above 90%. Thereafter, serum iron decreased to 51.6±9.7% of baseline at T=8 h in
the placebo group versus 84±15% and 60.4±8.9% of baseline at 24 h in the groups treated with iron sucrose and
deferasirox, respectively. No significant differences in the endotoxemia-induced cytokine response (TNF-α, IL-6,
IL-10 and IL-1RA), subclinical vascular injury and kidney injury were observed between groups. However, vascular
reactivity to noradrenalin was impaired in the 6 subjects in whom labile plasma iron was elevated during endo-
toxemia as opposed to those in whom no labile plasma iron was detected  (P=0.029). In conclusion, a single dose
of iron sucrose does not affect the innate immune response in a model of experimental human endotoxemia, but
may impair vascular reactivity when labile plasma iron is formed. (Clinicaltrials.gov identifier:01349699)
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immune response, and subclinical organ injury during sys-
temic inflammation induced by experimental endotox-
emia in humans in vivo. 
Methods 
Design 
This double-blind, randomized, placebo-controlled trial
(Clinicaltrials.gov identifier:01349699) was approved by the local
ethics committee, and carried out according to standards of Good
Clinical Practice and the Declaration of Helsinki. After written
informed consent, 30 healthy non-smoking male subjects were
randomly treated with either iron loading (iron sucrose), or iron
chelation (deferasirox) or placebo, prior to the intravenous admin-
istration of 2 ng/kg purified E.Coli endotoxin, as described in detail
in the Online Supplementary Methods.
Iron loading and iron chelation therapy
At T = -2 h (i.e. 2 h before endotoxin administration), iron chela-
tion therapy (deferasirox (Exjade®), Novartis, The Netherlands) or
placebo (starch powder) was administered orally. A commonly
applied dose of 30 mg/kg of deferasirox13 was dissolved in water
and was stirred until the moment of intake. Subjects drank the sus-
pension within 1 min. The time point of deferasirox administra-
tion was chosen so that maximal plasma levels were achieved
between 0 and 2 h after endotoxin administration, just before and
during the expected peak of the pro-inflammatory cytokine
response. At T = -1 h, a generally applied therapeutic dose14 of 1.25
mg/kg iron sucrose (Venofer®, Vifor Nederland BV, The
Netherlands), or placebo (NaCl 0.9%), was intravenously admin-
istered through blinded syringes and lines. Because the two thera-
pies had different administration routes, a double dummy was
used to ensure adequate blinding.
Iron homeostasis analysis
Serum iron, ferritin, transferrin and soluble transferrin receptor
(sTfR), hepcidin, GDF-15 and LPI were determined as described in
the Online Supplementary Design and Methods. 
Oxidative stress and cytokine measurements
Oxidative stress (malondialdehyde) and plasma levels of pro-
inflammatory cytokines TNF-α and IL-6, the anti-inflammatory
cytokines IL-10 and IL-1ra, and markers of endothelial activation
Vascular Cell Adhesion Molecule (VCAM) and Intercellular
Adhesion Molecule (ICAM) were determined as described in the
Online Supplementary Design and Methods. 
Subclinical organ injury 
Subclinical endothelial injury was assessed by measuring the
changes in response of the forearm vasculature to the infusion of
vasoactive medication into the brachial artery, using venous occlu-
sion plethysmography. For the determination of subclinical renal
tubular damage, urinary Glutathione S-Transferase Alpha-1-1
(GSTA1-1) and Glutathione S-Transferase-Pi-1-1 (GSTP1-1) were
determined. A detailed description is provided in the Online
Supplementary Design and Methods.
Stastistical analysis
Data are expressed as mean±SEM, or median (25th-75th per-
centile), depending on their distribution. P=0.05 was considered
statistically significant. For all outcome variables, the intervention
groups were compared to the placebo group in two separate
analyses.  Group means or medians were tested using Student's t-
test for parametric data and Mann Whitney-U test for non-para-
metric data. Changes over time for each treatment group were
analyzed by one-way ANOVA-repeated measures and post hoc
testing was performed with Dunnett's Multiple Comparison Test.
Differences over time between groups were analyzed using two-
way ANOVA repeated measures (interaction term: time*treat-
ment). Peak levels of cytokines were correlated to oxidative stress
levels using Spearman’s correlation coefficients. The analysis of
forearm blood flow (FBF) and a power calculation are described in
the Online Supplementary Design and Methods. 
Results
No significant differences between the intervention
groups with respect to demographic data and anti-oxida-
tive status were found (Table 1).  
Symptoms and hemodynamic sequelae
Iron sucrose and deferasirox treatment were well toler-
ated. Experimental endotoxemia resulted in flu-like symp-
toms (shivering, headache, backache, muscle ache and
nausea) that gradually declined to base-line values at the
end of the experiment (T=8 h). There were no differences
between the treatment groups, measured by a cumulative
subjective symptom scoring list that has been described
previously15 (data not shown). Body temperature in the
three treatment groups increased by 2.2±0.1°C; no differ-
ences were observed between groups. Also, the hemody-
namic response to endotoxemia (increase in heart rate of
25.6±1.7 bpm and decrease in mean arterial pressure of
11.5±1.5 mmHg) was not influenced by iron loading or
iron chelation treatment (Table 2).
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Table 1. Demographic data and anti-oxidative status.
Iron sucrose Deferasirox Placebo P
(n=10) (n=10) (n=10)
Demographic data
Age (years) 21.4±0.6 21.7±1.3 22.7±0.9 0.63
Weight (kg) 75.7±2.0 74.8±4.4 79.0±2.4 0.61
BMI kg/m2) 22.3±0.4 22.5±0.7 23.3±0.8 0.53
Forearm volume (mL) 1115±48 1066±70 1119±38 0.74
Anti-oxidative status
Vitamin A (μmol/L) 2.4±0.2 2.2±0.1 2.2±0.1 0.54
Vitamin C (μmol/L) 51.0±2.0 57.8±4.9 46.5±1.4 0.052
Vitamin E (μmol/L) 23.9±1.4 23.6±1.6 23.1±1.1 0.92
Bilirubin (μmol/L) 14.0±1.4 11.5±2.1 12.1±1.1 0.53
Total cholesterol (mmol/L) 4.4±0.2 4.0±0.2 4.2±0.1 0.28
Anti-oxidative status was measured at screening. Data expressed as mean±SEM. No differences
between groups were detected by one-way ANOVA.
Table 2. Hemodynamic changes during experimental endotoxemia.
Iron sucrose Deferasirox Placebo P
(n=10) (n=10) (n=10)
ΔHR (bmp) + 24.5±2.9 + 26.9±3.7 + 25.3±2.3 0.85
ΔSBP (mmHg) - 15.9±2.7 - 10.6±2.3 - 16.9±3.6 0.27
ΔMAP (mmHg) - 12.6±2.2 - 7.9±2.7 - 14.2±2.4 0.19
ΔDBP (mmHg) - 6.5±2.0 - 4.0±3.3 - 9.2±1.7 0.33
Difference (Δ: delta) between mean value of T=-4 to T= -2 h and T=4 and T=6 h after the adminis-
tration of endotoxin. HR: heart rate; MAP: mean arterial pressure; DBP: diastolic blood pressure.
Data are expressed as mean±SEM. No differences between groups were detected by one-way
ANOVA.
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Iron parameters
Administration of iron sucrose resulted in a big increase
in serum iron to 218±17% of baseline (Figure 1A). Serum
iron levels initially increased during LPS-induced systemic
inflammation in all three groups, reaching peak levels at
approximately 3 h after LPS administration, followed by a
gradual decrease, reaching its lowest values at T = 8 h in
the placebo group (51.6±9.7% of baseline) and 24 h in the
iron sucrose- and deferasirox-treated groups (84±15% and
60.4±8.9% of baseline, respectively). Transferrin satura-
Acute effect of iron on innate immunity
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Figure 1. Iron parameters. IS: iron sucrose; DFX: deferasirox; Plac: placebo; NS: not significant. Arrows indicate the time points of deferasirox
and iron sucrose administration.  Changes over time for each treatment group were analyzed by one-way ANOVA-repeated measures followed
by Dunnett’s post hoc test: †Significant change from baseline in iron sucrose group; *Significant change from baseline in deferasirox group.
#Significant change from baseline in placebo group. Differences between groups were analyzed using two-way ANOVA-repeated measures
(interaction term: time*treatment). The intervention groups were compared to the placebo group in separate analyses. Significant interac-
tions between treatments are depicted within each graph. Data are represented as mean±SEM. 
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tion showed the same profile (data not shown), peaking at
T = 3 h. Iron chelation did not reduce serum iron levels,
which can be explained by the fact that in the serum iron
analysis, the total of both chelated and unchelated iron is
determined.16 When serum iron was elevated, transferrin
saturations of over 90% were reached in 5 out of 10 iron
sucrose-treated subjects, whereas this was observed in
none of the deferasirox-treated and in 1 of the placebo-
treated subjects. Ferritin was increased at 3 h after LPS
administration, after which it reached a plateau in the
placebo- and deferasirox-treated group, while further
increasing in the iron sucrose-treated group (Figure 1B).
TIBC was increased at T = 24 h (Figure 1C), as was sTfR
(Figure 1D). GDF-15 peaked at 6 h post LPS (Figure 1E).
These last three parameters were not influenced by iron
loading or chelation treatment. Hepcidin was markedly
induced by LPS-induced inflammation, reaching its peak
levels at 6 h following LPS administration (Figure 1F).
Again, no differences between the treatment groups were
observed. Treatment with iron sucrose did not result in
measurable LPI levels at T = 0 (Figure 2A). However, at T
= 2  and 3 h, simultaneously to the endotoxin-induced rise
in serum iron and transferrin saturation, LPI was increased
in 5 out of 10 iron sucrose-treated subjects, compared to 1
placebo-treated subject (Figure 2A and B). Importantly, LPI
formation most notably occurred when transferrin satura-
tion was over 90% (Figure 2C).
Oxidative stress
The administration of iron sucrose induced a profound
increase in plasma lipid peroxidation products (MDA) at T
= 0 h (433±37% of baseline;  P<0.0001) (Figure 3). In this
group, MDA remained elevated in comparison with the
other two groups until 3 h after LPS administration. Three
hours after endotoxin administration, a similar inflamma-
tion-induced increase in MDA was observed in the place-
bo group (P=0.34) and the iron chelation group (P=0.008).
Iron administration did not potentiate the endotoxemia-
associated increase in oxidative stress at T = 3 h. MDA
increases were not related to LPI formation in any way. 
Plasma cytokines
Endotoxemia resulted in increased plasma levels of pro-
inflammatory cytokines (Figure 4A and B). The TNF-α
response was similar in the different groups. The increase
in IL-6 tended to be potentiated in the iron sucrose-treated
group compared with the other treatment groups
(P=0.052). No correlations between iron parameters and
pro-inflammatory cytokines were found. In particular, no
correlation was found between LPI or MDA and pro-
inflammatory cytokine production. 
The anti-inflammatory response, illustrated by plasma
levels of IL-10 and IL-1ra, was similar in all three groups
(Figure 4C and D). For the three groups combined, plasma
levels of ICAM and VCAM gradually increased after the
endotoxin challenge from 84±5 and 164±7 pg/mL to peak
levels of 161±12 (P<0.0001) and 259±10 ng/mL
(P<0.0001), respectively at T = 24 h (data not shown). Again,
no differences were observed between the treatment
groups and no correlations were found with iron parame-
ters.
Subclinical organ injury
Vascular reactivity as measured by changes in forearm
blood flow in response to intrabrachial infusion of vasoac-
tive drugs was reduced after endotoxemia (Figure 5).
Elevated MDA levels caused by infusion of iron sucrose
prior to endotoxemia were not associated with the inflam-
mation-induced vascular hyporesponsiveness, and iron
chelation had no ameliorating effects. However, subjects
in whom elevated LPI levels were found 2 or 3 h after
endotoxin administration (5 subjects in the iron sucrose
group and 1 in the placebo group) did show a more pro-
nounced inflammation-induced reduction of vascular reac-
tivity to noradrenalin compared with those who showed
no LPI increase (48.5%, range 19.7-80.8%) of base-line
L.T. van Eijk et al.
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Figure 2. Labile plasma iron and transferrin saturation. (A) Mean labile plasma iron levels in the 3 treatment groups. Changes over time for
each treatment group were analyzed by one-way ANOVA-repeated measures followed by Dunnett’s post hoc test: †Significant change from
baseline in iron sucrose group. No significant changes were detected in the other treatment groups. IS: iron sucrose. DFX: deferasirox. Data
are expressed as mean±SEM. (B) Transferrin saturation of the subjects in the iron sucrose-treated group. Open dots: samples in which no labile
plasma iron was detected, black dots: samples in which labile plasma iron was detected. Note that in general, labile iron was only positive in
subjects in whom transferrin saturation increased above 90%. (C) Labile plasma iron in relation to transferrin saturation in iron sucrose-treated
subjects at T = 2h and T = 3h.
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response in LPI positive subjects versus 84.3% (range 61.7-
121.1%) in LPI negative subjects (P=0.029). No correlation
between MDA and vascular dysfunction was observed.
The excretion of markers of subclinical kidney injury
GSTA1-1 (proximal tubule injury) and GSTP1-1 (distal
tubule injury) was increased after endotoxin administra-
tion in all three groups. Treatment with either iron sucrose
or deferasirox had no effect on the urinary excretion of
GSTA1-1 and GSTP1-1 in comparison to the placebo
group. Furthermore, excretion of these markers was not
related to LPI or oxidative stress. For the three groups
combined, median GSTA1-1 excretion increased from 234
ng/mmol (range 87-452 ng/mmol) creatinine at baseline to
1123 ng/mmol (611-2194 ng/mmol) creatinine at T = 12 h
after LPS treatment, and returned to base-line levels at T =
24 h (189 ng/mmol, range 52-309 ng/mmol). GSTP1-1
increased from 85 ng/mmol (range 32-209 ng/mmol) crea-
tinine at baseline to 1120 ng/mmol (414-1442 ng/mmol)
creatinine at T = 12 h and also normalized at T = 24 (154
ng/mmol, range 84-338 ng/mmol). 
Discussion
This study shows that administration of a single dose of
iron sucrose results in an increase in oxidative stress, while
it does not significantly modulate the acute innate
immune response or inflammation-induced end-organ
dysfunction in humans in vivo. In line with these findings,
iron chelation with a single dose of deferasirox did not
alter acute effects of  experimental endotoxemia in
healthy volunteers with regard to inflammation-induced
oxidative stress, the innate immune response, and subclin-
ical end-organ dysfunction. However, when transferrin
becomes saturated following iron sucrose infusion, forma-
tion of redox active LPI during endotoxemia is associated
with a more pronounced inflammation-induced reduction
in vascular reactivity to noradrenalin, indicating that in a
subgroup of subjects infused with iron sucrose, iron does
exert deleterious vascular effects during inflammation.
In accordance with previous studies,17,18 the administra-
tion of iron sucrose resulted in an increase in oxidative
stress, as reflected by the markedly elevated amount of
lipid peroxidation product MDA. In the present study, we
found that, while systemic inflammation elicited by endo-
toxemia increased oxidative stress, iron administration
does not potentiate the inflammation-induced oxidative
stress response or release of pro-inflammatory cytokines,
despite the increment in LPI that was observed in a sub-
group of iron sucrose-treated individuals. These findings
during systemic inflammation in humans in vivo are in con-
trast with previous findings in animals. Iron sucrose
administered together with heat-killed E.Coli in rats was
shown to significantly enhance cytokine production and
was associated with increased mortality.2 It was speculat-
ed that the iron sucrose-mediated increase in oxidative
stress was responsible for amplification of the inflamma-
tory response. Importantly, supra-pharmacological doses
of iron sucrose were used in the animals, being approxi-
mately 40 times higher than the dose generally adminis-
tered in humans19 and used in the present study.
Furthermore, the dose used in rats elicited a significant
increase in TNF-α in the absence of E. Coli.2 Therefore, the
difference in iron dosages may explain the difference in
results. Although we found a trend towards increased
endotoxemia-induced IL-6 peak levels in iron-treated sub-
jects, no effect on the production of TNF-α was observed,
indicating that pharmacological doses of iron do not have
any relevant influence on the innate immune response in
humans in vivo. Our findings correspond to clinical obser-
vations of patients suffering from inflammatory bowel
disease who are dependent on intravenous iron supple-
mentation to restore inflammation-associated anemia.
The majority of these patients experience no effects or
even a beneficial effect on inflammation-related disease
activity.20 However, since experimental endotoxemia is a
model of acute and short-lived systemic inflammation for
which we treated the subjects with a single bolus of iron
sucrose or deferasirox, we do acknowledge that  the
absence of an acute immune-modulating effect of iron in
the present study does not necessarily exclude a possible
effect of iron in chronically iron loaded patients, such as
those suffering from sickle cell disease, thalassemia or
chronic kidney disease. Furthermore, our study does not
rule out a possible immune-modulating role of hepcidin
during these chronic diseases.21 
We determined vascular reactivity and excretion of
markers of tubular damage in the urine as parameters of
inflammation-induced subclinical end-organ dysfunction.
In accordance with previous studies by our group22 and by
others,23 experimental endotoxemia resulted in vascular
hyporeactivity. Overall, iron sucrose treatment  did not
Acute effect of iron on innate immunity
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Figure 3. Oxidative stress. Malondialdehyde (MDA) concentrations as
a measure of oxidative stress. IS: iron sucrose; DFX: deferasirox; Plac:
placebo; NS: not significant. Arrows indicate the time points of
deferasirox and iron sucrose administration. #Effect of endotoxin
administration on oxidative stress. Changes over time for each treat-
ment group were analyzed by one-way ANOVA-repeated measures
followed by Dunnett’s post hoc test: †Significant change from base-
line in iron sucrose group; *Significant change from baseline in
deferasirox group. #Significant change from baseline in placebo
group. Changes over time were significant in the iron sucrose group
(P<0.0001) and the deferasirox group (P=0.008), but not in the
placebo group. Differences between groups were analyzed using two-
way ANOVA-repeated measures. The intervention groups were com-
pared to the placebo group in separate analyses. Significant interac-
tion between treatments are depicted within the graph. Data are rep-
resented as mean±SEM. †Significant change from baseline in iron
sucrose group. *Significant change from baseline in deferasirox
group.
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directly exacerbate inflammation-induced endothelial dys-
function. In a previous study in human volunteers in the
absence of systemic inflammation, it was found that
endothelial dysfunction of the brachial artery occurred fol-
lowing iron sucrose administration, but had been restored
at 4 h after administration.8 Therefore, in our study, the
endothelial damage that may have occurred due to the
oxidative stress caused by iron sucrose itself could have
subsided by the time inflammation-induced endothelial
dysfunction occurred.23 However, iron sucrose treatment
contributed to the saturation of transferrin that occurred at
T = 2-3 h after endotoxin administration, thereby con-
tributing to LPI formation. LPI formation was shown to be
associated with increased vascular dysfunction caused by
inflammation. We confirmed our previous findings that
endotoxemia induces subclinical renal damage of both the
proximal tubule and the distal tubule.24 Iron loading before
LPS administration did not modify the urinary excretion of
the tubular injury markers, indicating that iron does not
exert a direct toxic effect on tubular cells, and does not
exacerbate inflammation-induced tubular damage. 
Interestingly, LPI levels did not correlate with MDA.
Possibly this is the result of a large difference in plasma
half life whereby LPI only exists for a short time, whereas
MDA products are eliminated more gradually. Therefore,
as LPI was not measured directly following iron sucrose
L.T. van Eijk et al.
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Figure 4. Cytokine production during endotoxemia. Data are represented as median with interquartile range. Changes over time for each treat-
ment group were analyzed by one-way ANOVA-repeated measures followed by Dunnett’s post hoc test: Changes over time were significant in
all subgroups for all parameters. †Significant change from baseline in iron sucrose group; *Significant change from baseline in deferasirox
group. #Significant change from baseline in placebo group. Differences between groups were analyzed using two-way ANOVA-repeated meas-
ures. The intervention groups were compared to the placebo group in separate analyses. No significant interactions between treatments were
detected. As there was a trend towards a higher IL-6 in the iron sucrose group, peak levels for this parameter were additionally compared to
the placebo group using the Mann Whitney U test; P=0.052.
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treatment, we cannot exclude the possibility that there is
a correlation between LPI and MDA levels directly follow-
ing iron sucrose infusion.
Beneficial effects of iron chelator deferrioxamin on both
inflammatory parameters and outcome in rodent models
of sepsis have been reported.4-6 Moreover, iron chelation
therapy has been shown to work synergistically with
antibiotics in the treatment of murine sepsis.25,26 Several
explanations for the differences with our findings in
humans can be put forward. First of all, the majority of
studies in which a beneficial effect of iron chelation ther-
apy was found were performed in rodents or in vitro.
Besides the fact that extrapolation to humans may be
problematic, there are important differences in routes of
administration and dosages administered. In animals, the
iron chelator deferrioxamin is usually given as bolus injec-
tion, whereas in humans it needs to be administrated as a
slow infusion over 8-24 h to avoid possible toxicity asso-
ciated with high plasma levels. For this proof of principle
study, we aimed to reach a high concentration of iron
chelator between 0 and 2 h after endotoxin administra-
tion, the time window in which the inflammatory cascade
is being activated  and pro-inflammatory cytokines reach
their peak levels. Therefore, we chose to administer
deferasirox, a relatively new iron chelator that can be
administered orally at once, has a good bioavailability of
approximately 70%, with peak plasma levels between 2
and 4 h after ingestion,27 and has  been shown to protect
against oxidative stress-induced damage in patients.28-31
We chose a relatively high dosage of 30 mg/kg.32 Although
deferasirox has roughly the same characteristics as defer-
rioxamin with regard to the chelation of iron, there might
be a difference in anti-oxidative capacity between the two
compounds. While deferasirox exerts anti-oxidative
effects in animals models and patients,33 deferrioxamin
exerts anti-oxidative effects even after pre-saturation of
the deferrioxamin-molecule with iron,6 suggesting an anti-
oxidative effect of the molecule itself, while this has not
yet been established for deferasirox. The fact that
deferasirox may not exert anti-oxidative effects by itself
may in part explain why no effect on the inflammation-
induced oxidative stress was observed. The fact that
inflammation-induced oxidative stress was not attenuated
by deferasirox may also explain why no effect on inflam-
mation-induced endothelial dysfunction was found.
Furthermore, LPI formation could only be shown in 1 sub-
ject of the placebo group, so apparently there was not
much catalytically active iron present in the plasma for
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Figure 5. Vascular dysfunction. Vascular dysfunction measured by Forearm Blood Flow (FBF) measurements before endotoxin administration
(open circles) and 4-6 h after endotoxin administration (closed circles). In panels A, B and C dose response curves to Achetylcholine (Ach),
Nitroglycerin (NTG), Norepinephrine (NE) are presented, respectively. Increases and decreases in FBF were expressed as percentage change
from baseline. The results of all 30 subjects are combined in these three graphs, showing that the vascular responsiveness to Ach, NTG and
NE were significantly attenuated after endotoxin administration. Data are presented as mean±SEM. In panels D, E and F, the relative response
after LPS administration is expressed as a percentage of the response before endotoxin administration by comparing the area under the curve
(AUC) before and after endotoxemia to enable the evaluation of differences between the treatment groups. Data in these graphs are expressed
as median and interquartile range. No differences in relative decrease in vascular responsiveness were present between the 3 groups.
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deferasirox to chelate during experimental endotoxemia.
Finally, oxidative stress is only one of the factors that may
lead to vascular hyporeactivity during endotoxemia.
Other, local factors that are not influenced by anti-oxidant
therapy may also play a role, such as the upregulation of
inducible nitric oxide synthase34 and the activation of
potassium channels on vascular smooth muscle cells.22
It is generally known that inflammation results in a
reduction of serum iron. Here we report for the first time
that serum iron initially increases in the acute phase of
systemic inflammation, which is accompanied by LPI for-
mation once serum transferrin becomes saturated.
Although we did not investigate the mechanism underly-
ing the increase in serum iron in the present study, we
speculate that the acute release of pro-inflammatory
cytokines depresses the erythropoiesis in the bone mar-
row, while an iron flux from storage cells to the plasma is
still present, as hepcidin is not yet elevated. Previous stud-
ies indicated that pro-inflammatory cytokines, mainly
TNF-α, are able to suppress hematopoiesis in vitro and in
vivo.35-39 As the utilization of iron is attenuated, serum iron
increases, and only decreases after the induction of hep-
cidin and the decrease of TNF-α. In accordance with this,
the rate by which serum iron increased in the present
study roughly resembles the rate by which iron is normal-
ly utilized by the bone marrow (5 μmol/L/h ≈ 22 mg iron
per day for an average person).40 GDF-15 has been report-
ed both as a marker of innate immunity41 and a humoral
factor connecting increased or ineffective erythropoiesis in
the bone marrow to a  reduction of hepatocyte hepcidin
production.42 We observed a peak of GDF-15 at 6 h post
LPS, that is most likely attributed to the endotoxin-related
inflammation. Interestingly, and in agreement with recent
findings in mice suggesting that GDF-15 is not essential
for systemic iron homeostasis,43 this increase in GDF-15
did not prevent the increase of hepcidin after LPS admin-
istration. Surprisingly, iron loading had no effect on serum
hepcidin levels, despite a clear effect of serum iron and
transferrin saturation. This finding suggests that during
the acute inflammatory phase, transferrin bound-iron
induced hepcidin production does not add to cytokine-
dependent hepcidin induction.
In conclusion, a single dose of iron sucrose or
deferasirox does not exert relevant effects on the innate
immune response in a model of experimental human
endotoxemia. Acute systemic inflammation is associated
with an initial rise in serum iron and transferrin saturation
that is associated with LPI formation once transferrin sat-
urations over 90% are reached. LPI formation during
experimental human endotoxemia is associated with
more pronounced vascular dysfunction but not with other
measures of subclinical end organ injury.
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